Effects of GMCSF and HIV-1 infection on the expression of CD11a on monocyte-derived macrophages.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Effects of GMCSF and HIV-1 infection on the expression of CD11a on monocyte-derived macrophages.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:73 (abstract no. SB5). Unique Identifier : AIDSLINE ASHM5/94349033
Stent G; Crowe SM; Macfarlane Burnet Centre for Medical Research, Fairfield,; Australia.

Abstract: OBJECTIVES: To examine the kinetics and regulation of CD11a on monocytes (MO) and macrophages (Mphi). METHODS: Mphi were isolated from buffy coats (n = 4) by density gradient centrifugation and plastic adherence or elutriation. (1) MO were incubated with varying concentrations of GMCSF (0-500U/ml) on the day of isolation and surface stained with CD11a MAb (DAKO) at regular intervals. (2) Mphi were infected with HIV-1 (BaL) at 5d post isolation and stained weekly with anti-CD11a. HIV-1 p24 Ag expression was also determined by FACS. Percent positive cells and equivalent molecules of fluorescence (EMF) as determined by calibration beads, were quantitated by flow cytometry. RESULTS: (1) GMCSF upregulated CD11a expression on Mphi in a dose dependent manner: 500U/ml GMCSF, CD11a 91% staining (EMF 240,000.); no cytokine, CD11a 79% (EMF 92,000). (2) HIV-1 upregulated expression of CD11a: infected, CD11a 91% +/- 35 (EMF 283,000 +/- 105,000); uninfected, CD11a 83% +/- 5 (EMF 191,000 +/- 76,000). CONCLUSION: Both GMCSF and HIV-1 appear to upregulate surface expression of CD11a on Mphi. HIV may stimulate MO to produce GMCSF which could in turn upregulate CD11a expression. This is being investigated.

Keywords: Cell Line Gene Expression Regulation, Viral/DRUG EFFECTS Granulocyte-Macrophage Colony-Stimulating Factor/*PHARMACOLOGY Human HIV-1/*GENETICS Lymphocyte Function-Associated Antigen-1/*GENETICS Macrophages/IMMUNOLOGY/*MICROBIOLOGY Monocytes/IMMUNOLOGY/*MICROBIOLOGY Up-Regulation (Physiology)/GENETICS Virus Integration/*DRUG EFFECTS/GENETICS Virus Replication/*DRUG EFFECTS/GENETICS ABSTRACT
941230
M94C4194

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .